이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도에서 중증의 플라크 건선 환자를 대상으로 한 ORKA-001의 용량 탐색 연구 (EVERLAST-B)

2026년 11월 3일 업데이트: Oruka Therapeutics, Inc.

중등도에서 중증의 플라크 건선 환자를 대상으로 한 ORKA-001의 다기관, 무작위배정, 이중눈가림, 위약대조, 용량탐색 임상시험

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.

연구 유형

중재적

등록 (추정된)

160

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Baden-Wuerrtemberg
      • Heidelberg, Baden-Wuerrtemberg, 독일, 69120
        • Oruka Therapeutics Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, 독일, 60590
        • Oruka Therapeutics Investigative Site
    • Lower Saxony
      • Bad Bentheim, Lower Saxony, 독일, 48455
        • Oruka Therapeutics Investigative Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, 독일, 24105
        • Oruka Therapeutics Investigative Site
    • Arizona
      • Phoenix, Arizona, 미국, 85032
        • Oruka Therapeutics Investigative Site
    • Arkansas
      • North Little Rock, Arkansas, 미국, 72117
        • Oruka Therapeutics Investigative Site
    • California
      • Los Angeles, California, 미국, 90045
        • Oruka Therapeutics Investigative Site
      • Los Angeles, California, 미국, 90024
        • Oruka Therapeutics Investigative Site
      • San Diego, California, 미국, 92123
        • Oruka Therapeutics Investigative Site
    • Florida
      • Miami, Florida, 미국, 33126
        • Oruka Therapeutics Investigative Site
    • Illinois
      • Rolling Meadows, Illinois, 미국, 60008
        • Oruka Therapeutics Investigative Site
    • Indiana
      • Plainfield, Indiana, 미국, 46168
        • Oruka Therapeutics Investigative Site
    • Maryland
      • Rockville, Maryland, 미국, 20850
        • Oruka Therapeutics Investigative Site
    • New York
      • Kew Gardens, New York, 미국, 11415
        • Oruka Therapeutics Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27516
        • Oruka Therapeutics Investigative Site
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • Oruka Therapeutics Investigative Site
      • Mason, Ohio, 미국, 45040
        • Oruka Therapeutics Investigative Site
    • Oregon
      • Portland, Oregon, 미국, 97201
        • Oruka Therapeutics Investigative Site
      • Portland, Oregon, 미국, 97210
        • Oruka Therapeutics Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • Oruka Therapeutics Investigative Site
    • Texas
      • Frisco, Texas, 미국, 75033
        • Oruka Therapeutics Investigative Site
      • Houston, Texas, 미국, 77004
        • Oruka Therapeutics Investigative Site
      • Webster, Texas, 미국, 77598
        • Oruka Therapeutics Investigative Site
    • Virginia
      • Norfolk, Virginia, 미국, 23502
        • Oruka Therapeutics Investigative Site
    • Barcelona
      • Badalona, Barcelona, 스페인, 08916
        • Oruka Therapeutics Investigative Site
      • Barcelona, Barcelona, 스페인, 08041
        • Oruka Therapeutics Investigative Site
    • Madrid
      • Madrid, Madrid, 스페인, 28002
        • Oruka Therapeutics Investigative Site
      • Madrid, Madrid, 스페인, 28046
        • Oruka Therapeutics Investigative Site
    • British Columbia
      • Surrey, British Columbia, 캐나다, V3R 6A7
        • Oruka Therapeutics Investigative Site
      • Surrey, British Columbia, 캐나다, V3V 0C6
        • Oruka Therapeutics Investigative Site
    • New Brunswick
      • Fredericton, New Brunswick, 캐나다, E3B 1G9
        • Oruka Therapeutics Investigative Site
    • Ontario
      • Ajax, Ontario, 캐나다, L1S 7K8
        • Oruka Therapeutics Investigative Site
      • Markham, Ontario, 캐나다, L3P 1X3
        • Oruka Therapeutics Investigative Site
      • Peterborough, Ontario, 캐나다, K9J 5K2
        • Oruka Therapeutics Investigative Site
    • Quebec
      • Montreal, Quebec, 캐나다, HZX 2V1
        • Oruka Therapeutics Investigative Site
      • Québec, Quebec, 캐나다, G1V 4X7
        • Oruka Therapeutics Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Participants ≥ 18 years of age

  2. Have a diagnosis of plaque psoriasis for > 6 months

  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy

  5. Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known hypersensitivity to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: (Induction Period - Arm 1) ORKA-001

Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

실험적: (Induction Period - Arm 2) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

실험적: (Induction Period - Arm 3) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

위약 비교기: (Induction Period - Arm 4) Placebo

Participants will receive Placebo per protocol Induction regimen.

Placebo administered by subcutaneous (SC) injection

실험적: (Maintenance Period - Arm 1) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

실험적: (Maintenance Period - Arm 2) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

위약 비교기: (Maintenance Period - Arm 3) Placebo

Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

Placebo administered by subcutaneous (SC) injection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
기간: Week 16

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
기간: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
기간: Week 16

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
기간: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
기간: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
기간: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
기간: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
기간: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
기간: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
기간: Day 1 through Week 100

Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Day 1 through Week 100

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 12월 3일

기본 완료 (실제)

2026년 10월 21일

연구 완료 (추정된)

2028년 12월 1일

연구 등록 날짜

최초 제출

2025년 12월 16일

QC 기준을 충족하는 최초 제출

2025년 12월 16일

처음 게시됨 (실제)

2025년 12월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ORKA-001-114

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다